TMSP(SH:600671)2021-10-29 16:00Financial Performance - The company's operating revenue for Q3 2021 was CNY 22,606,417.08, representing a decrease of 53.70% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of CNY 8,979,353.05, with a year-to-date loss of CNY 15,129,707.34[5]. - The basic and diluted earnings per share for the quarter were both CNY -0.07, compared to CNY -0.12 in the same period last year[6]. - Total operating revenue for the first three quarters of 2021 was ¥99,821,256.47, a decrease from ¥160,113,947.23 in the same period of 2020, representing a decline of approximately 37.5%[24]. - The net profit for Q3 2021 was -¥16,400,778.04, compared to -¥4,583,781.37 in Q3 2020, reflecting a significant increase in losses[26]. - Basic and diluted earnings per share for Q3 2021 were both -¥0.1242, compared to -¥0.0338 in Q3 2020[26]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 418,885,254.88, down 5.34% from the end of the previous year[6]. - The equity attributable to shareholders decreased by 20.77% to CNY 57,713,741.24 compared to the end of the previous year[6]. - Total liabilities as of September 30, 2021, were CNY 341,953,694.81, a slight decrease of 2.5% from CNY 349,177,858.90[21]. - The company's total assets were CNY 418,885,254.88, down from CNY 442,510,197.01, reflecting a decrease of 5.34%[22]. Cash Flow - The company reported a cash flow from operating activities of CNY -2,515,433.45 year-to-date[6]. - Net cash flow from operating activities for the first three quarters of 2021 was -¥2,515,433.45, an improvement compared to -¥12,668,897.79 in the same period of 2020[29]. - The company reported a total cash inflow from operating activities of ¥93,030,160.72 for the first three quarters of 2021, compared to ¥171,116,625.20 in 2020, a decrease of about 45.4%[29]. - The company reported a net increase in cash and cash equivalents of $32,143,821.67, contrasting with a decrease of -$15,615,973.50 in the previous year[30]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,698[12]. - The top two shareholders held 42.54% of the total shares, with Qingdao Huilong Huaze Investment Co., Ltd. holding 22.01% and Yongxin Huari Cultural Development Co., Ltd. holding 20.53%[12]. - The top shareholder, Qingdao Huilong Huaze Investment Co., Ltd., holds 26,799,460 shares, representing 23.81% of the total share capital after signing a concerted action agreement[14]. - The company has a total of 29,000,028 shares held by the concerted action parties, making them the largest shareholder group[14]. - The company has a total of 10 major shareholders, with the top 5 holding significant stakes in the company[13]. Operational Challenges - The significant decline in revenue was attributed to the suspension of production for GMP transformation during the reporting period[10]. - The company is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, which poses a risk of forced delisting if found guilty[15]. - The company confirmed non-operating fund occupation by the former controlling shareholder amounting to RMB 28.84 million and illegal guarantees totaling RMB 3.31 million[15]. - The company has identified RMB 30.73 million in engineering prepayments and RMB 54.14 million in equity transfer payments as non-operating fund occupations[15]. - The company is actively cooperating with the regulatory investigation and adhering to disclosure obligations during this period[15]. Production and Development - The company is undergoing a GMP renovation of its production lines in a new facility, with the first phase focusing on eye drops and penicillin tablets[16]. - The company completed the BE clinical registration for its main product, Amoxicillin and Clavulanate Potassium Tablets, on July 12, 2021[18]. - The company has made progress in the consistency evaluation of its main product, with a total contract amount of CNY 11 million signed for the technical development[17]. - The production line for Amoxicillin and Clavulanate Potassium Tablets has resumed after passing the GMP compliance inspection[17]. Expenses - Total operating costs for the first three quarters of 2021 were ¥120,739,841.16, down from ¥172,888,643.61 in 2020, indicating a reduction of about 30.2%[24]. - Sales expenses for the first three quarters of 2021 were ¥16,288,662.11, down from ¥41,692,871.92 in 2020, a decrease of approximately 60.0%[24]. - Research and development expenses for the first three quarters of 2021 were ¥1,136,346.03, slightly down from ¥1,569,501.47 in 2020[24].